STING Platform

About Second Generation STING Agonists

All of Spring Bank’s second generation STING agonists are specifically designed to be conjugated with antibodies as antibody-drug conjugates (ADCs) for a possible targeted delivery approach. These compounds are potentially more potent than currently available STING modulators and have the potential to be administered intravenously.

About SB 11285

STimulator of INterferon Genes, or STING, is a protein that has the power to activate the body’s innate immune system. Targeting this protein gives us the potential to stimulate the body’s immune response in the presence of diseases such as cancer.


SB 11285 is a potent immunotherapeutic agent that activates the STING pathway. It is currently being developed for the treatment of selected cancers, including liver cancer. Due to its chemistry, SB 11285 has the potential to be conjugated to antibodies for a targeted delivery approach. SB 11285 can be administered intravenously.

Clinical Trials

In the third quarter of July 2019, the FDA accepted Spring Bank’s Investigational New Drug Application for SB 11285, the company’s intravenously-administerd STING agonist. We plan to commence a Phase 1 clinical trial in multiple cancers in 2019.